Protease Inhibitors and Phosphatase Inhibitors
Abcam HA14-1, Bcl-2 inhibitor. BH-3 mimetic., 10MG
MW 409.2 Da. Cell permeable Bcl-2 inhibitor. BH-3 mimetic. Disrupts Bax and Bcl-2 interactions. Apoptotic anticancer agent.
The product is subject to the following: Abcam Restricted Use Statement
Enzo Life Sciences Protease Inhibitor CocktaIL-(1Set)
Solubility: Soluble in aqueous buffers, or add directly to extraction media. Alternatively, prepare 7X stock solutions in 1.5ml water or 100mM phosphate buffer, pH 7.0. Long Term Storage: +4°C.
Cayman Chemical GPX4 InhIbItr 17 5mg
A GPX4 inhibitor and ferroptosis inducer; inhibits GPX4 activity by 49.16% at 1 µM; increases the production of ROS and levels of MDA in OS-RC-2 cells 0.5 µM; induces ferroptosis in HT-1080 cells (IC50s = 0.007 and 1.486 µM, in the absence and presence of ferrostatin-1, respectively); reduces tumor volume and intratumoral GPX4 levels in an OS-RC-2 mouse xenograft model 20 mg/kg
American Research Products Inc Mouse Plasma protease C1 inhib
Mouse Plasma protease C1 inhibitor (SERPING1) ELISA kit from CUSABIO Detection Range 5 6 ng/mL-360 ng/mL Sensitivity 1 4 ng/mL Sample serum plasma tissue homogenates Method Sandwich
Cayman Chemical JZL 195 InHBTr asy REGE 20nmol
JZL 195 inhibitor assay reagent has been formulated and tested to work with Cayman’s Assay Kits. Detailed instructions for its use are contained in the respective Cayman Assay Kit booklet.
Abcam AG 490, JAK2/3 inhibitor, 10MG
MW 294.3 Da, Purity >99%. JAK2/3 inhibitor (IC₅₀ values are ~10 and 25 μM, respectively). Inhibits downstream activation of STAT5a/b. Effects synaptic plasticity and cytokine-independent cell growth in vitro and spatial learning, memory and tumor cell invasion in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WHI-P131 hydrochloride, JAK3 inhibitor, 10MG
MW 297.31 Da, Purity >98%. Cell-permeable Janus kinase 3 (JAK3) inhibitor (IC₅₀ values of 9.1 μM and 78 μM for human and mouse recombinant proteins respectively). Selective versus JAK1, JAK2, SYK, BTK and LYN tyrosine kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Tetrabenazine, VMAT2 inhibitor, 25MG
MW 317.42 g/mol. Potent, reversible VMAT2 inhibitor (IC₅₀ = 3.2 nM, Ki = 100 nM). Depletes monoamines stores and decreases uptake into synaptic vesicles. Shows antihyperkinetic effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML7, myosin light chain kinase inhibitor, 10MG
MW 452.7 Da, Purity >99%. Potent and selective myosin light chain kinase inhibitor (MLCK) (Ki = 300 nM). Also inhibits PKA and PKC (Ki values are 21 and 42 μM, respectively). Cell-permeable. Inhibits tumor cell growth.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sivelestat, neutrophil elastase inhibitor, 5MG
MW 434.5 Da. Potent, selective, substrate competitive neutrophil elastase inhibitor (IC₅₀ values are 19-49 nM and 5.6 μM for leukocyte and pancreas elastase respectively). Suppresses neutrophil-induced capillary permeability and leukocyte kinetics. Active in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam LYS6K2, S6 kinase inhibitor, 25MG
MW 445.42 g/mol. Selective, cell-permeable S6 kinase inhibitor. Blocks phosphorylation of p70 ribosomal S6 kinase.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Gabe x ate mesylate, General serine protease inhibitor, 50MG
MW 417.5 Da, Purity >99%. General serine protease inhibitor (Ki values are 3.4 nM, 5, 1.8 μM and 2.6 mM at tryptase, thrombin, tyrpsin and kallikrein serine proteases respectively). Additionally inhibits nitric oxide synthase. Displays antithrombotic activity and antitumor effect. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Cayman Chemical CathepsIn G InhIbItr I 500ug
A cathepsin G inhibitor (IC50 = 53 nM); selective for cathepsin G over thrombin, Factor Xa, Factor IXa, plasmin, trypsin, and PR3 (IC50s = >100 µM for all), but also weakly inhibits chymotrypsin; inhibits cathepsin G-induced activation of IL-36 in neutrophil degranulates at 10 µM; reduces CD4+ T cell-induced secretion of IFN-γ and IL-17 in B cells incubated with TTC and also reduces TTC presentation in B cells at 10 µM; decreases the size of neuromyelitis optica lesions and reduces the number of perivascular neutrophils when used in combination with sivelestat in a mouse model of IgG-induced brain injury at 5 UG/animal
Cayman Chemical nutrophIl Elasts InhIbItr 25mg
An N-benzoylindazole derivative that selectively targets the binding domain of neutrophil elastase (IC50 = 7 nM)